Calcbench: 72 percent of S&P 500 companies reported adjusted earnings in 2025, pushing non-GAAP net income higher than "traditional" GAAP net income by $271 billion

Calcbench/Suffolk found 361 S&P 500 firms adjusted FY2025 net income or EPS, reporting adjusted net income $271B higher than GAAP. Eighty-seven percent adjusted upward, with some companies (e.g., AbbVie, Broadcom, Capital One, GM, Pfizer) showing adjusted figures multiple times GAAP. Notably, investment-related adjustments swung to -$7.9B in 2025 from +$26.5B in 2024 (a $33.5B shift), underscoring how non-GAAP presentation can materially alter earnings narratives.

Analysis

This is a quality-of-earnings and multiple-discipline story, not a near-term fundamental catalyst. When management teams consistently normalize away costs, investors eventually stop capitalizing the headline EPS and start underwriting free cash flow, which is a negative for any name still relying on “adjusted” optics to defend premium multiples.

The highest-risk names are the ones where the gap between adjusted and GAAP earnings is large enough to alter the valuation anchor: ABBV, PFE, and GM are more exposed because their core businesses already face either patent, regulatory, or cyclical pressure. AVGO is different: the market is accustomed to aggressive non-GAAP framing, so the stock should be more resilient unless cash conversion slips, at which point the de-rating can be sharp because the bull case is heavily cash-flow dependent.

The more interesting second-order signal is the swing in investment-related adjustments. That suggests corporate treasuries and balance sheets are becoming enough of a profit center that mark-to-market noise can contaminate earnings quality, especially for financials and cash-rich sectors if rates or asset prices move against them. In a risk-off tape, that can turn from a footnote into a consensus haircut on reported profitability.

Contrarian take: the market usually treats these reconciliations as cosmetic, but the real information content is whether excluded items are recurring and whether management is quietly financing EPS stability with add-backs. If that pattern persists into the next reporting season while cash flow and guidance stay flat, the penalty is likely multiple compression rather than an immediate earnings miss.

Key Decisions for Investors

• No standalone directional trade from this report; use it as a quality screen and require GAAP/FCF confirmation before adding to ABBV, PFE, GM, or AVGO over the next 1-3 months.
• Relative-value idea: long QUAL or RSP / short a basket of ABBV, PFE, and GM into the next earnings cycle; target 3-5% spread if the market starts rewarding cleaner earnings over adjusted EPS, with a stop if the basket outperforms by 2%.
• For AVGO, trade only on cash conversion and backlog, not adjusted EPS; if free-cash-flow conversion deteriorates, fade rallies with a 1-2 month short call or a stock/XLK pair trade.
• Watch for a widening GAAP-to-adjusted gap in upcoming filings; if add-backs expand again quarter-over-quarter, that is a credibility break and a signal to cut exposure rather than average down.